June 4, 2019 / 5:51 PM / 4 months ago

BRIEF-Novartis AG Says Long-Term Survival Benefit Shown For Metastatic Melanoma Patients Treated With Novartis Tafinlar + Mekinist

June 4 (Reuters) - Novartis AG:

* NOVARTIS AG SAYS LONG-TERM SURVIVAL BENEFIT SHOWN FOR METASTATIC MELANOMA PATIENTS TREATED WITH NOVARTIS TAFINLAR® + MEKINIST® Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below